Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAdrian SchwarzerWFWalter FiedlerDLDavid de Leeuw

Discussion

Loading...

Member takes

Overview

Phase I clinical study shows NK cell therapy achieves MRD negativity in some AML patients, suggesting potential benefits.

Key Points

  • The study aims to evaluate the safety and efficacy of NK cells derived from umbilical cord blood in AML patients.
  • Multicenter, open-label, phase I clinical trial
  • Evaluated cryopreserved UCB CD34+ HSC-derived NK cells after lymphodepleting regimen
  • Assessed safety, tolerance, and MRD response in AML patients with measurable residual disease
  • 41% of patients achieved MRD negativity with NK cell infusions
  • One-year survival rate was 50% for all patients
  • No adverse events related to NK cells reported, indicating therapy was well tolerated

Cite This Study

Schwarzer et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e473https://doi.org/10.1182/blood-2025-1640
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp>2024 · 35 citations
  2. 2Allogeneic Cd56+ Cell Infusion As A Bridge To Hematopoietic Stem Cell Transplantation In Relapsed/Refractory Acute Myeloid Leukemia: A Phase I Clinical Trial2025
  3. 3Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT2025
  4. 4Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia2025 · 3 citations
  5. 5NK cell adoptive transfer in acute myeloid leukemia: a systematic review and meta-analysis2026